Background In recent years, several bispecific antibodies (BsAbs) have been introduced that
revolutionized the treatment approach for patients with multiple myeloma (MM). In the …

Despite the results achieved with the evolution of conventional chemotherapy and the
inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is …

Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-
targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on …

Introduction Glioblastoma, isocitrate dehydrogenase wildtype (IDHwt), remains an incurable
disease despite considerable research effort. The current standard of care since 2005 …

Bispecific antibodies (BsAbs) form an exciting class of bio-therapeutics owing to their
multispecificity. Although numerous formats have been developed, generation of hetero …

Antibodies are crucial tools in various biomedical applications, including immunotherapy. In
this study, we focused on designing and engineering antibodies to enhance their structural …

Several new drugs and regimens have greatly improved outcomes in multiple myeloma, but
the rapid emergence of new targets and immune-based modalities has added significant …

CAR T-cell therapies have revolutionized the treatment of various B-cell malignancies [1–3].
Although allogeneic stem cell transplantation first demonstrated the power of adoptive T-cell …

Als AML bezeichnet man eine Erkrankung von hämatopoetischen Zellen, die durch
genetische Veränderung zu einer Deregulation in Wachstum und Differenzierung dieser …

Cancer immunotherapy is undergoing rapid development. Numerous preclinical and clinical
trials are in progress. In general terms, immunotherapy includes non-specific stimulation of …